Cargando…

Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo

Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsD...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Chenghao, Mao, Yingqing, Wu, Tao, Kang, Nannan, Zhao, Mingjun, Di, Rongrong, Li, Xiaoping, Ji, Xuemei, Liu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213929/
https://www.ncbi.nlm.nih.gov/pubmed/30257416
http://dx.doi.org/10.3390/ijms19102900
_version_ 1783367890374754304
author Xiong, Chenghao
Mao, Yingqing
Wu, Tao
Kang, Nannan
Zhao, Mingjun
Di, Rongrong
Li, Xiaoping
Ji, Xuemei
Liu, Yu
author_facet Xiong, Chenghao
Mao, Yingqing
Wu, Tao
Kang, Nannan
Zhao, Mingjun
Di, Rongrong
Li, Xiaoping
Ji, Xuemei
Liu, Yu
author_sort Xiong, Chenghao
collection PubMed
description Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsDb) that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 (PD-1) in Pichia pastoris. Under the optimal expression conditions (methanol concentration, 1%; pH, 4.0; inoculum density, OD600 = 4, and the induction time, 96 h), the maximum production level of this BsDb is achieved at approximately 20 mg/L. The recombinant BsDb is purified in one step using nickel-nitrilotriacetic acid (Ni-NTA) column chromatography with a purity of more than 95%. Indirect enzyme-linked immune sorbent assay (ELISA) and sandwich ELISA analyses show that purified BsDb can bind specifically to VEGF165 and PD-1 simultaneously with affinities of 124.78 nM and 25.07 nM, respectively. Additionally, the BsDb not only effectively inhibits VEGF165-stimulated proliferation, migration, and tube formation in primary human umbilical vein endothelial cells (HUVECs), but also significantly improves proliferation and INF-γ production of activated T cells by blocking PD-1/PD-L1 co-stimulation. Furthermore, the BsDb displays potent antitumor activity in mice bearing HT29 xenograft tumors by inhibiting tumor angiogenesis and activating immune responses in the tumor microenvironment. Based on these results, we have prepared a potential bispecific antibody drug that can co-target both VEGF165 and PD-1 for the first time. This work provides a stable foundation for the development of new strategies by the combination of an angiogenesis inhibition and immune checkpoint blockade for cancer therapy.
format Online
Article
Text
id pubmed-6213929
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62139292018-11-14 Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo Xiong, Chenghao Mao, Yingqing Wu, Tao Kang, Nannan Zhao, Mingjun Di, Rongrong Li, Xiaoping Ji, Xuemei Liu, Yu Int J Mol Sci Article Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsDb) that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 (PD-1) in Pichia pastoris. Under the optimal expression conditions (methanol concentration, 1%; pH, 4.0; inoculum density, OD600 = 4, and the induction time, 96 h), the maximum production level of this BsDb is achieved at approximately 20 mg/L. The recombinant BsDb is purified in one step using nickel-nitrilotriacetic acid (Ni-NTA) column chromatography with a purity of more than 95%. Indirect enzyme-linked immune sorbent assay (ELISA) and sandwich ELISA analyses show that purified BsDb can bind specifically to VEGF165 and PD-1 simultaneously with affinities of 124.78 nM and 25.07 nM, respectively. Additionally, the BsDb not only effectively inhibits VEGF165-stimulated proliferation, migration, and tube formation in primary human umbilical vein endothelial cells (HUVECs), but also significantly improves proliferation and INF-γ production of activated T cells by blocking PD-1/PD-L1 co-stimulation. Furthermore, the BsDb displays potent antitumor activity in mice bearing HT29 xenograft tumors by inhibiting tumor angiogenesis and activating immune responses in the tumor microenvironment. Based on these results, we have prepared a potential bispecific antibody drug that can co-target both VEGF165 and PD-1 for the first time. This work provides a stable foundation for the development of new strategies by the combination of an angiogenesis inhibition and immune checkpoint blockade for cancer therapy. MDPI 2018-09-25 /pmc/articles/PMC6213929/ /pubmed/30257416 http://dx.doi.org/10.3390/ijms19102900 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xiong, Chenghao
Mao, Yingqing
Wu, Tao
Kang, Nannan
Zhao, Mingjun
Di, Rongrong
Li, Xiaoping
Ji, Xuemei
Liu, Yu
Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title_full Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title_fullStr Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title_full_unstemmed Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title_short Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
title_sort optimized expression and characterization of a novel fully human bispecific single-chain diabody targeting vascular endothelial growth factor165 and programmed death-1 in pichia pastoris and evaluation of antitumor activity in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213929/
https://www.ncbi.nlm.nih.gov/pubmed/30257416
http://dx.doi.org/10.3390/ijms19102900
work_keys_str_mv AT xiongchenghao optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT maoyingqing optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT wutao optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT kangnannan optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT zhaomingjun optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT dirongrong optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT lixiaoping optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT jixuemei optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo
AT liuyu optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo